NASDAQ NMS - GLOBAL MARKET · SKYE

-3.93% · -$0.0700 · Vol 93.5K

Market closed · last close 4:00 PM ET · price as of 16:00:00 ET

Skye Bioscience Inc

Biotechnology

$1.71

Card

Relationship Map

Follow $SKYE

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $SKYE by email

Veridion Score

BETALOW CONF · 4 of 6 factors measured

Stale score · Mon Sep 21 · completed session · 27h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET · SKYE

Methodology

Tue Sep 22 snapshot unavailable for SKYE. Cause unavailable.

Valuation absence reason unknown · Sentiment absence reason unknown

SKYE

Skye Bioscience Inc

Stale score · Mon Sep 21 · completed session · 27h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET

37/100

Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

37/ 100

Veridion Score

Lower range · LOW confidence · 4 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: LOW · 4 of 6 factors measured · Stale score · Mon Sep 21 · completed session · 27h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is SKYE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move SKYE next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Coverage building

No dated catalysts found for SKYE in the current source window. The page stays empty rather than inventing an event without a receipt.

About Skye Bioscience Inc

PHARMACEUTICAL PREPARATIONS

Listed since

2014

Employees

Country

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$1.78

Day high

$1.81

Day low

$1.62

Previous close

$1.78

52W high

$38.00

-95.50% from high

52W low

$1.57

0% of range

Market cap

$7.9M

EPS

$-1.3500

Beta

0.34

Shares out

4.4M

Volume

93.5K

0.60× rel vol

Avg volume

155K

VWAP

$1.69

Price history computed in-house

+0.59%

-21.20%

-69.83%

-94.21%

YTD

-71.49%

SMA 50 $3.32 · below

SMA 200 $5.75 · below

52W position 0%

SKYE overview

Veridion Score

Registered · 2026-09-21

4 of 6 factors measured

Latest receipt rows

No recent disclosure on file.

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around SKYE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

SKYE insider activity

Skye Bioscience Inc

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

Form 4 evidence state

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in SKYE

Congress tracker Open ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for SKYE in the cached public ledger.

Federal contracts

SKYE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for SKYE in this window.

Lobbying spend

SKYE lobbying filings, year to date.

Registered lobbying filings matched to Skye Bioscience Inc.

Not disclosed

Refresh interval: 12hSource: LDA disclosure filings

No lobbying filings on file for SKYE in this window.

Analyst ratings

Sovereign unlock shows live analyst consensus for SKYE.

Options

Sovereign unlock shows live options positioning for SKYE.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Methodology

No related ticker met the data requirements for this rail.

Follow $SKYE

Why is SKYE moving today?

What can move SKYE next.

SKYE overview

Related filings and maps

SKYE insider activity

SKYE contract awards, year to date.

SKYE lobbying filings, year to date.

Cross-references from this score page.

What can move SKYE next.

SKYE insider activity

Cross-references from this score page.